ANL 0.00 Decreased By ▼ -15.34 (-100%)
ASC 13.22 Decreased By ▼ -0.02 (-0.15%)
ASL 17.53 Decreased By ▼ -0.07 (-0.4%)
BOP 8.65 Decreased By ▼ -0.05 (-0.57%)
BYCO 7.29 Increased By ▲ 0.09 (1.25%)
FCCL 19.10 Increased By ▲ 0.66 (3.58%)
FFBL 0.00 Decreased By ▼ -22.95 (-100%)
FFL 0.00 Decreased By ▼ -15.05 (-100%)
FNEL 0.00 Decreased By ▼ -7.09 (-100%)
GGGL 0.00 Decreased By ▼ -16.70 (-100%)
GGL 27.89 Increased By ▲ 0.09 (0.32%)
HUMNL 6.78 Increased By ▲ 0.08 (1.19%)
JSCL 19.25 No Change ▼ 0.00 (0%)
KAPCO 27.25 Increased By ▲ 0.55 (2.06%)
KEL 3.34 Decreased By ▼ -0.08 (-2.34%)
MDTL 0.00 Decreased By ▼ -2.14 (-100%)
MLCF 0.00 Decreased By ▼ -35.30 (-100%)
NETSOL 0.00 Decreased By ▼ -101.20 (-100%)
PACE 0.00 Decreased By ▼ -4.11 (-100%)
PAEL 26.49 Increased By ▲ 0.30 (1.15%)
PIBTL 0.00 Decreased By ▼ -8.14 (-100%)
POWER 0.00 Decreased By ▼ -7.25 (-100%)
PRL 0.00 Decreased By ▼ -16.11 (-100%)
PTC 0.00 Decreased By ▼ -9.04 (-100%)
SILK 0.00 Decreased By ▼ -1.47 (-100%)
SNGP 0.00 Decreased By ▼ -39.97 (-100%)
TELE 0.00 Decreased By ▼ -16.55 (-100%)
TRG 0.00 Decreased By ▼ -126.00 (-100%)
UNITY 29.35 Decreased By ▼ -0.55 (-1.84%)
WTL 0.00 Decreased By ▼ -2.38 (-100%)
BR100 4,733 Increased By ▲ 3.3 (0.07%)
BR30 20,339 Increased By ▲ 22.52 (0.11%)
KSE100 45,544 Decreased By ▼ -34.5 (-0.08%)
KSE30 17,811 Decreased By ▼ -60.87 (-0.34%)

Hilton Pharma, a top research based pharmaceutical company of Pakistan and manufacturer of quality medicines is supporting National Institute of Blood Disease (NIBD) in conducting a clinical trial where blood plasma collected from recovered COVID-19 patients is transfused to moderate and severely ill patients of COVID-19.

The initial results of 14 patients released by Dr. Tahir Shamsi of NIBD, shows a promising response of up to more than 80% recovery rate; Patients were administered with plasma therapy at the stage of moderate to severe disease and their condition was eventually prevented from further deterioration or progressing to a stage requiring ventilator. These initial outcomes also conform to the results of similar ongoing trials across the world. The trial will continue to have enough local patient data to help medical community in developing guidelines about the use of plasma therapy in COVID-19 patients.

"It is quite heartening to see these initial trial results as they will eventually create enough evidence for doctors and scientists to overcome the eminent threat looming over the world, at large," said Dr. Tahir Shamsi. "We are extremely hopeful that plasma therapy may serve as a great breakthrough. This is an orthodox way of treatment used in other pandemics in the absence of a proven treatment."

Dr. Tahir Shamsi started this initiative in Pakistan and to support his efforts Hilton Pharma provided a research grant and partnered technically with the clinical trial team. The trial is being conducted in various hospitals of Sindh, Punjab, and KPK. The plasma of a recovered patient contains antibodies which when injected in an active patient of COVID-19, helps in fighting the virus and provides the patient with sufficient time to develop his [or her] own immunity to combat the virus.

This trial of national importance is approved by all Provincial Governments, Bioethics Committees, Ministry of National Health Services Regulations & Coordination, and Pharmacy Services of DRAP. The trial is also registered globally with WHO and FDA trial site.-PR

Copyright Business Recorder, 2020

Comments

Comments are closed.